Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspra Approved For First-Line CHF; Pfizer Expects Most Use Will Be Add-On

Executive Summary

Pfizer's Inspra is expected to be primarily used as add-on therapy for congestive heart failure despite FDA approval of the selective aldosterone blocker for first-line use

You may also be interested in...



Pfizer Launches Inspra; Will Help Company Reach $54 Bil. In 2004

Pfizer is beginning its launch of the congestive heart failure therapy Inspra

Pfizer Launches Inspra; Will Help Company Reach $54 Bil. In 2004

Pfizer is beginning its launch of the congestive heart failure therapy Inspra

Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?

Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon

Related Content

UsernamePublicRestriction

Register

PS042613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel